Meeder Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Meeder Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-70	Closed	-$2K	–	2114
2022 Q3	$2K	Buy	70 +6	+9%	+$220	﹤0.01%	1877
2022 Q2	$3K	Sell	64 -13	-17%	-$597	﹤0.01%	1847
2022 Q1	$4K	Buy	+77	New	+$3.7K	﹤0.01%	1890
2021 Q4	–	Sell	-34	Closed	-$2K	–	2437
2021 Q3	$2K	Buy	34 +17	+100%	+$836	﹤0.01%	2238
2021 Q2	$1K	Sell	17 -14	-45%	-$578	﹤0.01%	2419
2021 Q1	$1K	Sell	31 -21	-40%	-$975	﹤0.01%	2283
2020 Q4	$2K	Buy	52 +10	+24%	+$468	﹤0.01%	1550
2020 Q3	$2K	Buy	42 +34	+425%	+$1.49K	﹤0.01%	1888
2020 Q2	$0	Buy	+8	New	+$399	﹤0.01%	2552
2020 Q1	–	Sell	-741	Closed	-$44K	–	2580
2019 Q4	$44K	Buy	741 +519	+234%	+$31K	﹤0.01%	1060
2019 Q3	$12K	Buy	222 +181	+441%	+$10.2K	﹤0.01%	1483
2019 Q2	$2K	Buy	+41	New	+$2.14K	﹤0.01%	1892
2018 Q4	–	Sell	-2,097	Closed	-$146K	–	1835
2018 Q3	$146K	Buy	2,097 +231	+12%	+$17.5K	0.01%	556
2018 Q2	$141K	Buy	1,866 +1,305	+233%	+$82.1K	0.01%	566
2018 Q1	$30K	Buy	561 +379	+208%	+$22K	﹤0.01%	787
2017 Q4	$9K	Sell	182 -660	-78%	-$36.7K	﹤0.01%	1167
2017 Q3	$50K	Buy	842 +120	+17%	+$7.26K	0.01%	685
2017 Q2	$57K	Buy	722 +668	+1,237%	+$54.6K	0.01%	660
2017 Q1	$4K	Hold	54	–	–	﹤0.01%	1192
2016 Q4	$4K	Buy	+54	New	+$3.92K	﹤0.01%	886
2016 Q3	–	Sell	-1,197	Closed	-$46K	–	972
2016 Q2	$46K	Sell	1,197 -5,327	-82%	-$222K	﹤0.01%	735
2016 Q1	$264K	Sell	6,524 -15,810	-71%	-$1M	0.02%	533
2015 Q4	$1.98M	Buy	+22,334	New	+$1.76M	0.18%	136

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Meeder Asset Management's EGRX Position: Q4 2022 in Review

Meeder Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 70 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in EGRX in Q4 2015 and held it in 23 quarters. The position peaked at $1.98M in Q4 2015. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

Meeder Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 70 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $2K.
Meeder Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 23 quarters.
Meeder Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $1.98M in Q4 2015.
152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.